



Cogstate Limited
ABN 80 090 975 723

Level 2, 255 Bourke Street
Melbourne Victoria 3000
Australia

P +61 3 9664 1300
F +61 3 9664 1301
W cogstate.com

ASX Announcement

10 March 2020

Notification of Change of Director's Interests

Cogstate (ASX.CGS) has announced that Cogstate CEO, Mr Brad O'Connor, has sold 550,000 Cogstate Ltd ordinary shares at \$0.42 per share, raising total sale proceeds of \$229,729.50, after costs.

The sale of securities was undertaken in order to fund the exercise of 1,100,000 options to acquire 1,100,000 ordinary shares in Cogstate Ltd. The options, with an exercise price of \$0.21 per share, were approved for issue at the 2015 Annual General Meeting of Cogstate and expire on 20 March 2020. The total cost of exercise of the options is \$231,000.

Upon settlement of the sale proceeds and then exercise of the options, the appropriate disclosure notices will be lodged with the ASX.

Mr O'Connor's holdings in Cogstate, both before and after the above mentioned transactions, are outlined in the table below:

	Pre-Transactions	Post-Transactions
Ordinary shares held directly	4,405,929	4,955,929
Ordinary shares held indirectly	917,173	917,173
Employee options	2,850,000	1,750,000

This announcement was authorised for release by a sub-committee of the Board of Directors of Cogstate Ltd.

About Cogstate

Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For nearly 20 years, Cogstate has proudly supporting the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. In the Healthcare market, Cogstate has recently entered into an exclusive licensing agreement with pharmaceutical company, Eisai, under which Eisai will market Cogstate technologies as digital cognitive assessment tools in Japanese markets. For more information, please visit www.cogstate.com.

For further information contact:

Brad O'Connor
Cogstate Chief Executive Officer
boconnor@cogstate.com